Role of Proton Pump Inhibitor in the Management of Acid-Related Disorders
作者： Elli Arsita , Achmad Fauzi
DOI: 10.24871/151201431-7
关键词:
摘要: Proton pump inhibitor (PPI) is the strongest to gastric acid secretion. PPI effective in all gastricacid disorders, such as: peptic ulcer, gastroesofageal reflux disease, non steroid anti inflammatory drugs (NSAIDs)gastropathy, and Zollinger-Ellison syndrome. Several studies comparing one another. Although somedifferences have been reported, there are small differences with unclear clinical importance.PPI has side effects that may be related diarrhea due Clostridium difficile, pneumonia, hip fracture, vitamin B12 deficiency, IgE mediated allergic reaction. revealed strong association but havelimitation design sampel size. therapy should according indication, dose, appropriate period. Keywords : proton inhibitor, disorder, period ABSTRAK Penghambat pompa (PPP) adalah paling kuat terhadap sekresi asam lambung. PPPefektif untuk terapi semua gangguan lambung termasuk ulkus peptikum, penyakit reflux,gastropati karena obat inflamasi (OAINS), dan sindrom Zollinger-Ellison. Beberapa penelitianmembandingkan beragam PPP satu dengan yang lainnya. Walaupun dilaporkan ada beberapa perbedaan,namun besaran perbedaannya kecil tidak jelas kepentingan klinisnya.PPP kemungkinan berkaitan efek samping diare frakturpanggul, defisiensi B12, reaksi alergi dimediasi IgE. penelitian menunjukkanhubungan namun memiliki keterbatasan desain sampel. Terapi harus sesuai denganindikasi, dosis, jangka waktu tepat. Kata kunci penghambat proton, lambung, indikasi,
sci-hub.st 参考文章(20)
Cristin A. Kiley, Douglas J. Cragin, Bernard J. Roth, Omeprazole-associated digoxin toxicity. Southern Medical Journal. ,vol. 100, pp. 400- 402 ,(2007) , 10.1097/SMJ.0B013E31802F34EA
Jai Moo Shin, Michel Homerin, Florence Domagala, Hervé Ficheux, George Sachs, Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+-ATPase in vitro and in vivo Biochemical Pharmacology. ,vol. 71, pp. 837- 849 ,(2006) , 10.1016/J.BCP.2005.11.030
M. Michael Wolfe, Robert C. Lowe, Investing in the future of GERD Journal of Clinical Gastroenterology. ,vol. 41, ,(2007) , 10.1097/MCG.0B013E318032390F
Emily R. Hajjar, Angela C. Cafiero, Joseph T. Hanlon, Polypharmacy in elderly patients American Journal of Geriatric Pharmacotherapy. ,vol. 5, pp. 345- 351 ,(2007) , 10.1016/J.AMJOPHARM.2007.12.002
Paul Moayyedi, David Armstrong, Richard H Hunt, Yao Lei, Margaret Bukoski, Robert J White, The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS—A Cluster-Randomized Trial American Journal of Gastroenterology. ,vol. 105, pp. 2341- 2346 ,(2010) , 10.1038/AJG.2010.368
Jai Moo Shin, Young Moon Cho, George Sachs, Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. Journal of the American Chemical Society. ,vol. 126, pp. 7800- 7811 ,(2004) , 10.1021/JA049607W
Denis M. McCarthy, Trent P. McLaughlin, Deborah L. Griffis, Cyrus Yazdani, Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. American Journal of Therapeutics. ,vol. 10, pp. 330- 340 ,(2003) , 10.1097/00045391-200309000-00005
Peter J. Kahrilas, Gastroesophageal Reflux Disease JAMA: The Journal of the American Medical Association. ,vol. 276, pp. 983- 988 ,(1996) , 10.1001/JAMA.1996.03540120061035
K. H. Liu, M. J. Kim, J. H. Shon, Y. S. Moon, S. Y. Seol, W Kang, I. J. Cha, J. G. Shin, Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro Xenobiotica. ,vol. 35, pp. 27- 38 ,(2005) , 10.1080/00498250400026472
T FURUTA, N SHIRAI, F WATANABE, S HONDA, K TAKEUCHI, T IIDA, Y SATO, M KAJIMURA, H FUTAMI, S TAKAYANAGI, Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clinical Pharmacology & Therapeutics. ,vol. 72, pp. 453- 460 ,(2002) , 10.1067/MCP.2002.127637